Condition: Idiopathic Intracranial Hypertension (IIH) · Sponsor: University Hospital, Montpellier
This study is aimed at patients suffering from long term intracranial hypertension (caracterized by visual loss, chronic headache and/or tinnitus), receiving acetazolamide for more than 1 year, having inadequate response to treatment (untolerable side effects or insufficient efficacy). The goal is to evaluate if stenting of a specific vein in the brain could decrease the hypertension and improve associated symptoms. Patients will be randomly assigned in either best medical care group (recommended medication associated with weight loss) or interventional group (best medical care + stenting of the specific vein) and will undergo specific follow-up visits after 1, 3 and 12 months.
This description comes directly from the study's public registry record.
Vincent COSTALAT, MD, PhD · +33 467 337 532 · v-costalat@chu-montpellier.fr
Fédérico CAGNAZZO, MD, PhD · +33 467 337 532 · f-cagnazzo@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| CHU de Montpellier Hôpital Gui de Chauliac | Montpellier, France | Recruiting |
| CHU de Reims | Reims, France | Not Yet Recruiting |
| CHU de Toulouse | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06945848